Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.

Bruton J. and Hanke T., (2025), Vaccines (Basel), 13

In danger: HIV vaccine research and development in Europe.

Tatoud R. et al, (2025), PLOS Glob Public Health, 5

Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK.

Borthwick N. et al, (2024), Lancet Microbe

PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated

Marin M. et al, (2024)

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.

Del Moral-Sánchez I. et al, (2024), NPJ Vaccines, 9

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.

Kopycinski J. et al, (2023), Sci Rep, 13

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.

Bailón L. et al, (2022), Nat Med

Include forthcoming?